Vaginal estrogens for the treatment of dyspareunia

Journal of Sexual Medicine

Volumn 8, Issue 3, 2011, Pages 666-674

  Krychman, Michael L ^a  

^a Southern California Center for Sexual Health and Survivorship Medicine   (United States)

Author keywords

Dyspareunia; Estrogen Therapy; Hormone Therapy; Postmenopausal Women; Vaginal Atrophy; Vaginal Therapy

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; LUBRICATING AGENT; PLACEBO; POLYCARBOPHIL;

ANORGASMIA; ATROPHIC VAGINITIS; CANDIDIASIS; CLINICAL ASSESSMENT; CREAM; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIAL DISEASE; ENDOMETRIAL PROLIFERATION; ENDOMETRIUM; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE SEXUAL DYSFUNCTION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; LOW DRUG DOSE; MEDICAL LITERATURE; MEDLINE; PATIENT COUNSELING; POSTMENOPAUSE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SELF REPORT; SEXUAL BEHAVIOR; SEXUAL SATISFACTION; STEADY STATE; SUPPOSITORY; SYSTEMATIC REVIEW; TABLET; THERAPY EFFECT; TRANSVAGINAL ECHOGRAPHY; TREATMENT INDICATION; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA RING; VAGINAL PRURITUS; VAGINITIS;

EID: 79951978815     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02114.x     Document Type: Article

References (74)

1. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas 2004;49:292-303.
2. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-6.
3. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-6.
4. Stenberg A, Heimer G, Ulmsten U, Cnattingius S. Prevalence of genitourinary and other climacteric symptoms in 61-year-old women. Maturitas 1996;24:31-6.
5. Willhite LA, O'Connell MB. Urogenital atrophy: Prevention and treatment. Pharmacotherapy 2001;21:464-80.
6. Altman A. Postmenopausal dyspareunia-A problem for the 21st century. OBG Manag 2009;21:37-44.
7. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357-69.
8. Kelley C. Estrogen and its effect on vaginal atrophy in post-menopausal women. Urol Nurs 2007;27:40-5.
9. Traish AM, Botchevar E, Kim NN. Biochemical factors modulating female genital sexual arousal physiology. J Sex Med 2010;7:2925-46.
10. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(1 suppl):S46-52.
11. Lara LAS, Useche B, Ferriani RA, Reis RM, de Sá MFS, de Freitas MMS, Rosa e Silva JC, da Sá Rosa e Silva ACJ. The effects of hypoestrogenism on the vaginal wall: Interference with the normal sexual response. J Sex Med 2009;6:30-9.
12. Samsioe G. Urogenital aging-A hidden problem. Am J Obstet Gynecol 1998;178:S245-9.
13. Cutler WB, Garcia CR, McCoy N. Perimenopausal sexuality. Arch Sex Behav 1987;16:225-34.
14. American College of Obstetricians and Gynecologists Task Force on Hormone Therapy. Sexual dysfunction. Obstet Gynecol 2004;104:85S-91S.
15. Dennerstein L, Lehert P, Burger H, Dudley E. Factors affecting sexual functioning of women in the mid-life years. Climacteric 1999;2:254-62.
16. Wylie KR. Sexuality and the menopause. J Br Menopause Soc 2006;12:149-52.
17. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-7.
18. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006;13:737-43.
19. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88:222-8.
20. Graziottin A. Dyspareunia and vaginismus: Review of the literature and treatment. Curr Sex Health Rep 2008;5:43-50.
21. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: Systematic review. BMJ 2006;332:749-55.
22. Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med 2010;7:314-26.
23. Frey K. Dyspareunia. In: Loue S, Sajatovic M, eds. Encyclopedia of women's health. New York, NY: Kluwer Academic/Plenum Publishers; 2004:234-5.
24. Basson R, Leiblum S, Brotto L, Derogatis L, Fourcroy J, Fugl-Meyer K, Graziottin A, Heiman JR, Laan E, Meston C, Schover L, van Lankveld J, Schultz WW. Definitions of women's sexual dysfunction reconsidered: Advocating expansion and revision. J Psychosom Obstet Gynecol 2003;24:221-9.
25. Kao A, Binik YM, Kapuscinski A, Khalife S. Dyspareunia in postmenopausal women: A critical review. Pain Res Manag 2008;13:243-54.
26. Barlow DH, Samsioe G, van Geelen JM. A study of European womens' experience of the problems of urogenital ageing and its management. Maturitas 1997;27:239-47.
27. Maartens LW, Leusink GL, Knottnerus JA, Smeets CG, Pop VJ. Climacteric complaints in the community. Fam Pract 2001;18:189-94.
28. Oskay UY, Beji NK, Yalcin O. A study on urogenital complaints of postmenopausal women aged 50 and over. Acta Obstet Gynecol Scand 2005;84:72-8.
29. Cumming GP, Currie HD, Moncur R, Lee AJ. Web-based survey on the effect of menopause on women's libido in a computer-literate population. Menopause Int 2009;15:8-12.
30. Dennerstein L, Guthrie JR, Hayes RD, Derogatis LR, Lehert P. Sexual function, dysfunction, and sexual distress in a prospective, population-based sample of mid-aged, Australian-born women. J Sex Med 2008;5:2291-9.
31. Cumming GP, Herald J, Moncur R, Currie H, Lee AJ. Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: A web-based survey. Menopause Int 2007;13:79-83.
32. Kellogg S, Kingsberg SA, Krychman M. Revealing Vaginal Effects At mid-Life (REVEAL). 2009. Available at: (accessed January 15, 2010).
33. Kingsberg SA, Kellogg S, Krychman M. Treating dyspareunia caused by vaginal atrophy: A review of treatment options using vaginal estrogen therapy. Int J Women's Health 2009;2:1-6.
34. ® estradiol vaginal ring 2mg [package insert]. New York, NY: Pharmacia & Upjohn Company, Division of Pfizer Inc.; 2007.
35. ® estradiol vaginal tablets [package insert]. Princeton, NJ: Novo Nordisk Pharmaceuticals, Inc.; 2003.
36. ® (conjugated estrogens) vaginal cream [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2008.
37. ® cream (estradiol vaginal cream, USP, 0.01%) [package insert]. Rockaway, NJ: Warner Chilcott, Inc.; 2007.
38. ® [package insert]. Pomona, NY: Duramed Pharmaceuticals, Inc.; 2008.
39. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:171-6.
40. Weisberg E, Ayton R, Darling G, Farrell E, Murkies A, O'Neill S, Kirkegard Y, Fraser IS. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 2005;8:83-92.
41. Simon JA, Snabes MC. Menopausal hormone therapy for vasomotor symptoms: Balancing the risks and benefits with ultra-low doses of estrogen. Expert Opin Investig Drugs 2007;16:2005-20.
42. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500.
43. Crandall C. Vaginal estrogen preparations: A review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt) 2002;11:857-77.
44. Ayton RA, Darling GM, Murkies AL, Farrell EA, Weisberg E, Selinus I, Fraser ID. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996;103:351-8.
45. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997;71:73-80.
46. Nachtigall LE. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995;22:S43-7.
47. Smith P, Heimer G, Lindskog M, Ulmsten U. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 1993;16:145-54.
48. Pinkerton JV, Shifren JL, La VJ, Rosen A, Roesinger M, Siddhanti S. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003;10:45-52.
49. Bachmann G. The estradiol vaginal ring-A study of existing clinical data. Maturitas 1995;22(suppl):S21-9.
50. Akrivis C, Varras M, Thodos A, Hadjopoulos G, Bellou A, Antoniou N. Action of 25 microg 17β-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women; clinical study. Clin Exp Obstet Gynecol 2003;30:229-34.
51. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Obstet Gynecol 2008;111:67-76.
52. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-7.
53. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: A double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 1992;44:137-44.
54. Mainini G, Scaffa C, Rotondi M, Messalli EM, Quirino L, Ragucci A. Local estrogen replacement therapy in postmenopausal atrophic vaginitis: Efficacy and safety of low dose 17beta-estradiol vaginal tablets. Clin Exp Obstet Gynecol 2005;32:111-3.
55. Mettler L, Olsen PG. Long-term treatment of atrophic vaginitis with low-dose oestradiol vaginal tablets. Maturitas 1991;14:23-31.
56. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-61.
57. Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-60.
58. Mandel FP, Geola FL, Meldrum DR, Lu JH, Eggena P, Sambhi MP, Hershman JM, Judd HL. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133-9.
59. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-52.
60. Raymundo N, Yu-cheng B, Zi-yan H, Lai CH, Leung K, Subramaniam R, Bin-rong C, Ling YS, Nasri N, Calimon N. Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 2004;7:312-8.
61. Bachmann G, Bouchard C, Hoppe D, Ranganath R, Altomare C, Vieweg A, Graepel J, Helzner E. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009;16:719-27.
62. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med 2010;7:1284-90.
63. Mazur D, Vens-Cappell B, Lohmann K, Breckwoldt M. Fractionated use of a 17β estradiol cream for the treatment of vaginal atrophy in postmenopausal women. Geburtshilfe und Frauenheilkunde 2005;65:584-9.
64. Freedman M, Kaunitz AM, Reape KZ, Hait H, Shu H. Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. Menopause 2009;16:735-41.
65. Creasman WT. Endometrial cancer: Incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 1997;24:S1-140-S1-150.
66. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on the endometrium. Obstet Gynecol 1994;84:215-8.
67. Schneider JP. Bisphosphonates and low-impact femoral fractures: Current evidence on alendronate-fracture risk. Geriatrics 2009;64:18-23.
68. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008;51:549-55.
69. Mishra G, Kuh D. Sexual functioning throughout menopause: The perceptions of women in a British cohort. Menopause 2006;13:880-90.
70. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: A meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005;7:R535-40.
71. Zielinski SL. Hormone replacement therapy for breast cancer survivors: An answered question? J Natl Cancer Inst 2005;97:955.
72. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
73. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 1997;65:89-93.
74. Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: An up-to-date overview. Climacteric 2008;12:91-105.